Commentary

Article

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

In Partnership With:

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

Speakers

  • Arpita Desai, MD I UCSF Helen Diller Family Comprehensive Cancer Center
  • Rahul Aggarwal, MD I UCSF Helen Diller Family Comprehensive Cancer Center
  • Terence Friedlander, MD I UCSF Helen Diller Family Comprehensive Cancer Center

Presentations

  • Frontline Treatment of Metastatic Urothelial Carcinoma
  • Case Presentation: mUC
  • Current Standard of Care in First Line and Later Line Therapy in mRCC
  • Updates in Metastatic HSPC
  • Navigating PARP Inhibitors in Metastatic CRPC
  • Emerging Targets in Prostate Cancers
Related Videos
Jun Gong, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Renee Saliby, MD, MSc
Roger Li, MD,
Marc-Oliver Grimm, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Antonio Cigliola, MD
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Related Content
Eliav Barr, MD, of Merck Research Laboratories
July 26th 2024

Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Matthew R. Cooperberg, MD, MPH, of UCSF
July 18th 2024

Prostate Cancer Test Is Missing Early Disease in Transgender Women

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Darrin Beaupre, MD, PhD
July 15th 2024

IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
July 11th 2024

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer